http://www.gsk.com/media/ GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news. http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10126.htm Endorsement is first for vaccine for pneumococcal disease - a life-threatening disease affecting many children; follows first-ever World Pneumonia Day Fri, 6 Nov 2009 15:30:00 GMT http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10126.htm http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10124.htm Pivotal testing of RTS,S is on track for target enrollment of 16,000 children Tue, 03 Nov 2009 10:30:00:00 GMT http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10124.htm http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10123.htm Dr Dominique Limet, CEO of ViiV Healthcare, promises 'relentless pursuit' of new treatments Tue, 03 Nov 2009 08:00:00 GMT http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10123.htm http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10122.htm GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International (VRX) announced today that, on 30 October, they filed a New Drug Application with the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMEA), for retigabine, used as adjunctive therapy to treat adult epilepsy patients with partial-onset seizures Mon, 2 Nov 2009 13:00:00 GMT http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10122.htm http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10121.htm - Benlysta (belimumab) 10 mg/kg plus standard of care met its primary efficacy endpoint by achieving a statistically significant improvement in patient response rate versus placebo plus standard of care at Week 52 in BLISS-76 - Primary efficacy endpoint met in two pivotal Phase 3 trials, as specified by Special Protocol Assessment agreement with FDA Mon, 02 Nov 2009 08:45:00 GMT http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10121.htm http://www.gsk.com/investors/quarterly_results.htm GlaxoSmithKline plc (GSK) announced third quarter results for 2009 Wed, 28 Oct 2009 12:00:00 GMT http://www.gsk.com/investors/quarterly_results.htm http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10119.htm GlaxoSmithKline (GSK) today announced that this week, approximately half a million people will have received its pandemic H1N1 vaccine, Pandemrix™, as part of Government initiated vaccination programmes across Europe, which commenced earlier this month Tue, 27 Oct 2009 14:00:00 GMT http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10119.htm http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10117.htm GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the first patient has commenced treatment as part of the Phase III programme being undertaken to develop a next-generation combination treatment for patients with chronic obstructive pulmonary disorder (COPD), a leading cause of chronic illness and death. Tue, 27 Oct 2009 12:00:00 GMT http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10117.htm http://www.gsk.com/media/pressreleases/2009/2009_us_pressrelease_10077.htm GSK and Genmab announced the accelerated approval of ArzerraTM (ofatumumab) from the US Food and Drug Administration for use in patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab. Mon, 26 Oct 2009 23:59:59 GMT http://www.gsk.com/media/pressreleases/2009/2009_us_pressrelease_10077.htm http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10116.htm GlaxoSmithKline (GSK) today announced that, to date, more than 150,000 people have received GSK's pandemic H1N1 vaccine, Pandemrix™, as part of Government initiated vaccination programmes across Europe which commenced last week. Fri, 23 Oct 2009 13:00:00 GMT http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10116.htm.htm